Epidemiological studies have consistently indicated that the prevalence of depression decreases with increasing age. Researchers have debated whether this finding is a real age-dependent decline or an artefact of sampling and assessment.
Treatment and Intervention
The current program of research seeks to investigate new and emerging statistical models to develop accurate and efficient diagnostic instruments that measure the latent relationship between internalising (eg. depression, anxiety), externalising (eg.
Platform 70 is a project of the National Partnership Agreement on Homelessness and commenced in 2011. The project has the following key objectives:
Cannabis is the most widely used illicit drug in Australia and its use is associated with an increased risk of involvement in motor vehicle accidents, work place accidents, mental health disorders, and respiratory and other health harms.
Attention Deficit Hyperactivity Disorder (ADHD) is a significant risk factor for the development of substance use disorders (SUD) in adolescence and adulthood, and ADHD complicates the course and treatment of SUD.
This project focuses on a common clinical problem that causes substantial functional, economic, and health impacts; comorbid depression and alcohol use. These conditions are under-treated and peak in young adulthood.
Prisoners are a marginalised group placing considerable costs on society. They experience very high rates of drug dependence, health problems and premature mortality. Without intervention they are highly likely to come into further health risk.
Trauma and post traumatic stress disorder (PTSD) are highly prevalent among people with substance use disorders.
Alcohol exposure in utero can cause a range of abnormalities in the fetus which are included under the umbrella term Fetal Alcohol Spectrum Disorders (FASD).
The National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn (the Guidelines) were commissioned by the Ministerial Council on Drug Strategy and